On Monday, 2150 stocks advanced, 1575 declined and 137 remained unchanged on the Bombay Stock Exchange (BSE), with an advance decline ratio of 1.36, indicating a positive closing of stocks in broader markets.
The deal, which is for the next five years, is for the supply of new-age patented life science active ingredient, the company said. In May, the firm renewed a $53 million contract with a German firm
Anupam Rasayan shares rose 6% after the Indian specialty chemical firm signed an LoI worth $265m with a Japanese peer for a new life science active ingredient. The supply of the product will begin after the validation process, lasting about 18 months. According to Anand Desai, MD of Anupam Rasayan, the company is "fully backward integrated for this molecule" and can provide its customers with "supply chain assurance" without being reliant on other sources of supply. The new customer diversifies Anupam Rasayan s client base, which already includes Japanese multinationals and Indian chemical manufacturers as customers.
On Wednesday, 1940 stocks advanced, 1640 declined and 123 remained unchanged on the Bombay Stock Exchange (BSE), with an advance decline ratio of 1.18 indicating a positive closing of stocks in broader markets. Markets were cautious ahead of the outcome of the US Federal Open Market Committee (FOMC) meeting on Thursday. Due to underperformance in the banking index, the current rally in the markets lacks decisiveness.
On Tuesday, 84 stocks, including Tata Communications, Oracle Financial, Dixon Technologies, Cummins India, and Astral, saw a long build-up, as per based on the OI percentage.